检索结果-南通市图书馆

中华结核和呼吸杂志 1997年第Z1期20卷 91-91页

作者： Saito H tsukiji j Fu L Nishikawa M Ikeda H Okubo T 曾小明(译) FirstDepartmentofInternalMedicine YokohamaCityUniversitySchoolofMedicineYokohamaJapan

来源：

同方期刊数据库评论

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

Randomized trial of chemoradiotherapy and adjuvant chemotherapy with nimustine (ACNU) versus nimustine plus procarbazine for newly diagnosed anaplastic astrocytoma and glioblastoma (jCOG0305)

引用

中国神经肿瘤杂志 2013年第1期11卷 21-21页

作者： Shibui S Narita Y Mizusawa j Beppu T Ogasawara K Sawamura Y Kobayashi H Nishikawa R Mishima K Muragaki Y Maruyama T Kuratsu j Nakamura H Kochi M Minamida Y Yamaki T Kumabe T Tominaga T Kayama T Sakurada K Nagane M Kobayashi K Nakamura H Ito T Yazaki T Sasaki H Tanaka K Takahashi H Asai A Todo T Wakabayashi T Takahashi j Takano S Fujimaki T Sumi M Miyakita Y Nakazato Y Sato A Fukuda H Nomura K Department of Neurosurgery and Neuro-Oncology National Cancer Center Hospital5-1-1 TsukijiChuo-kuTokyo 104-0045Japan

Objectives: Glioblastoma(GBM) is one of the worst cancers in terms of *** therapy consists of resection with concomitant *** to nimustine hydrochloride(ACNU),an alkylating agent,has been linked to methylguanine DNA methyltransferase(MGMT).Daily administration of procarbazine(PCZ) has been reported to decrease MGMT *** study investigated the efficacy of ACNU + PCZ compared to ACNU alone for GBM and anaplastic astrocytoma(AA).Methods: Patients(20-69 years) who had newly diagnosed AA and GBM were randomly assigned to receive radiotherapy with ACNU alone or with ACNU + *** primary endpoint was overall survival(OS).This was designed as a phase Ⅱ/Ⅲ trial with a total sample size of 310 patients and was registered as UMIN-CTR ***: After 111 patients from 19 centers in japan were enrolled,this study was terminated early because temozolomide was newly approved in *** median OS and median progression-free survival(PFS) with ACNU alone(n = 55) or ACNU + PCZ(n = 56) in the intention-to-treat population were 27.4 and 22.4 months(P = 0.75),and 8.6 and 6.9 months,*** median OS and median PFS of the GBM subgroup treated with ACNU alone(n = 40) or ACNU + PCZ(n = 41) were 19.0 and 19.5 months,and 6.2 and 6.3 months,*** 3/4 hematologic adverse events occurred in more than 40% of patients in both arms,and 27% of patients discontinued treatment because of adverse ***: The addition of PCZ to ACNU was not beneficial,in comparison with ACNU alone,for patients with newly diagnosed AA and GBM.

关键词：星形细胞母细胞随机试验放疗胶质变性化疗 MGMT

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：